Latest news with #JulianHarrison
Globe and Mail
12 hours ago
- Business
- Globe and Mail
Analysts Offer Insights on Healthcare Companies: Spyre Therapeutics (SYRE) and UnitedHealth (UNH)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Spyre Therapeutics (SYRE – Research Report) and UnitedHealth (UNH – Research Report) with bullish sentiments. Confident Investing Starts Here: Spyre Therapeutics (SYRE) BTIG analyst Julian Harrison maintained a Buy rating on Spyre Therapeutics yesterday and set a price target of $70.00. The company's shares closed last Tuesday at $15.18. According to Harrison is a 3-star analyst with an average return of 1.1% and a 41.2% success rate. Harrison covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, Rani Therapeutics Holdings, and Mereo Biopharma Group Plc. ;'> The word on The Street in general, suggests a Strong Buy analyst consensus rating for Spyre Therapeutics with a $56.83 average price target, implying a 237.1% upside from current levels. In a report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $50.00 price target. UnitedHealth (UNH) Bernstein analyst Lance Wilkes assigned a Buy rating to UnitedHealth yesterday and set a price target of $377.00. The company's shares closed last Tuesday at $308.87. According to Wilkes is a 2-star analyst with an average return of 0.0% and a 41.3% success rate. Wilkes covers the Healthcare sector, focusing on stocks such as Molina Healthcare, Elevance Health, and HCA Healthcare. ;'> Currently, the analyst consensus on UnitedHealth is a Moderate Buy with an average price target of $367.68, representing a 19.6% upside. In a report issued on June 2, KeyBanc also maintained a Buy rating on the stock with a $400.00 price target.
Yahoo
09-05-2025
- Business
- Yahoo
J&J's oral psoriasis drug helps patients achieve clear skin in late-stage study
(Reuters) -Johnson & Johnson said on Friday its experimental psoriasis drug met the main goal of a late-stage study, as the once-daily pill helped patients achieve clear or almost clear skin. The drugmaker has been working on more convenient treatment options as its injectable psoriasis drug Stelara, which gained over $10 billion in sales last year, faces stiff competition from cheaper rivals. J&J said last month it expects the drug, icotrokinra, to generate sales of $700 million in 2028. BTIG analyst Julian Harrison expects icotrokinra to "complement rather than disrupt" market leaders, including J&J's Tremfya and AbbVie's Skyrizi. Icotrokinra helped 66% of patients with scalp psoriasis and 77% of those with genital psoriasis achieve significantly clear skin compared to 11% and 21% success rate in patients on placebo, respectively, J&J said. The drug was administered to patients 12 years and older with at least moderate plaque psoriasis affecting "high-impact" areas, including the scalp and genitals, for 16 weeks. Plaque psoriasis, an immune-mediated condition characterized by thick, scaly patches or plaques, is the most common type of psoriasis. Psoriasis is estimated to affect more than 7.5 million adults in the United States. The study enrolled 311 patients, who were randomly chosen to receive either icotrokinra or placebo for a period of 16 weeks. J&J is developing the drug with partner Protagonist Therapeutics. Icotrokinra is designed to block a protein, IL-23, involved in inflammatory responses and is being tested as a potential treatment for other inflammatory conditions, such as ulcerative colitis. In a separate late-stage study last year, the drug showed significant skin clearance in patients with moderate-to-severe plaque psoriasis. Sign in to access your portfolio
